Global Retirement Partners LLC Purchases Shares of 7,179 IQVIA Holdings Inc. $IQV

Key Points

• Global Retirement Partners purchased 7,179 IQVIA shares worth approximately $1.39 million in the second quarter; institutional investors collectively own 89.62% of the company.
• IQVIA exceeded quarterly expectations with $3.15 in EPS and $4.37 billion in revenue, while revenue rose 8.7% year over year. The company also authorized a $2 billion share-buyback program covering up to 6.8% of outstanding shares.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and a $241.88 price target, although insiders sold 12,913 shares worth about $3.10 million over the past three months.

Global Retirement Partners LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 7,179 shares of the medical research company's stock, valued at approximately $1,387,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Financial Freedom LLC acquired a new position in IQVIA in the first quarter worth approximately $25,000. Ascentis Independent Advisors bought a new stake in IQVIA in the first quarter worth approximately $25,000. International Assets Investment Management LLC bought a new stake in IQVIA in the fourth quarter worth approximately $27,000. Gilpin Wealth Management LLC acquired a new position in IQVIA during the fourth quarter worth $27,000. Finally, CrossGen Wealth LLC bought a new position in IQVIA during the fourth quarter valued at about $28,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

Insiders Place Their Bets

In other news, insider W Richard Staub sold 5,500 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the transaction, the insider directly owned 13,312 shares of the company's stock, valued at $3,097,436.16. This represents a 29.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric Sherbet sold 5,000 shares of the company's stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the transaction, the insider owned 20,999 shares in the company, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 12,913 shares of company stock valued at $3,098,793. Corporate insiders own 1.70% of the company's stock.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $241.09 on Tuesday. The firm's 50 day simple moving average is $207.80 and its 200 day simple moving average is $186.72. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $251.36. The company has a market capitalization of $39.68 billion, a price-to-earnings ratio of 29.91, a P/E/G ratio of 2.01 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts' consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business's revenue was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA announced that its board has authorized a share buyback program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are typically a sign that the company's board believes its shares are undervalued.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Royal Bank Of Canada lifted their price target on IQVIA from $221.00 to $247.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 29th. Robert W. Baird boosted their target price on shares of IQVIA from $252.00 to $287.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 29th. TD Cowen increased their price target on shares of IQVIA from $233.00 to $288.00 and gave the company a "buy" rating in a report on Wednesday, July 29th. Morgan Stanley restated an "equal weight" rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a research note on Thursday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $241.88.

IQVIA Company Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source